Zoetis Inc. (ETR:ZOE)
| Market Cap | 48.24B |
| Revenue (ttm) | 8.01B |
| Net Income (ttm) | 2.26B |
| Shares Out | n/a |
| EPS (ttm) | 5.06 |
| PE Ratio | 21.35 |
| Forward PE | 19.26 |
| Dividend | 1.78 (1.68%) |
| Ex-Dividend Date | Oct 31, 2025 |
| Volume | 40 |
| Average Volume | 1,103 |
| Open | 107.68 |
| Previous Close | 106.60 |
| Day's Range | 107.68 - 107.68 |
| 52-Week Range | 101.00 - 172.60 |
| Beta | 0.96 |
| RSI | 40.10 |
| Earnings Date | Nov 4, 2025 |
About Zoetis
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]
Full Company ProfileFinancial Performance
In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.
Financial numbers in USD Financial StatementsNews
Zoetis Inc To Host Innovation Webcast Transcript
Zoetis Inc To Host Innovation Webcast Transcript
Zoetis Inc. (ZTS) Discusses R&D Pipeline Progress and Strategic Vision in Animal Health Innovation - Slideshow
2025-12-02. The following slide deck was published by Zoetis Inc.
Zoetis Inc. (ZTS) Discusses R&D Pipeline Progress and Strategic Vision in Animal Health Innovation Transcript
S&P 500 Movers: ZTS, APP
In early trading on Tuesday, shares of Applovin topped the list of the day's best performing components of the S&P 500 index, trading up 6.4%. Year to date, Applovin registers a 104.8% gain. And the w...
Zoetis Inc. (ZTS) Announces Upcoming Innovation Webcast
Zoetis Inc. (ZTS) Announces Upcoming Innovation Webcast
Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast
Zoetis Inc. (NYSE: ZTS), the world’s leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to provide an update on its proven innovation model, robust and diversified R&...
Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS), the world's leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to provide an update...
Top 15 High-Growth Dividend Stocks For December 2025
The Top 15 High-Growth Dividend Stocks for December 2025 offer a 1.58% yield and 20.97% five-year dividend growth, appearing 33% undervalued. The watchlist's goal is a 12% long-term CAGR, with Novembe...
2 Stocks to Buy Near Their 52-Week Lows
Not all stocks are soaring, but that may provide opportunity for long-term investors. Pinterest is hitting a lot of the right notes that could set it up for long-term success.
Zoetis (ZTS) Gains EU Approval for Lenivia in Canine Osteoarthritis
Zoetis (ZTS) Gains EU Approval for Lenivia in Canine Osteoarthritis
Zoetis (ZTS) Gains EU Approval for Canine Osteoarthritis Therapy Lenivia
Zoetis (ZTS) Gains EU Approval for Canine Osteoarthritis Therapy Lenivia
Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the re...
Zoetis Receives European Commission Marketing Authorization for Lenivia (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs...
Paul Harris' Top Picks: FirstService, Zoetis & Adobe
Paul Harris, partner and portfolio manager at Harris Douglas Asset Management, shares his top stock picks to watch in the market.
Zoetis Osteoarthritis Pain Franchise Needs A Reset: Analyst
As the animal health industry navigates a rapidly evolving landscape, companies are increasingly challenged to maintain their competitive edge through innovation and strategic adaptation. ZTS shares a...
Zoetis Osteoarthritis Pain Franchise Needs A Reset: Analyst
As the animal health industry navigates a rapidly evolving landscape, companies are increasingly challenged to maintain their competitive edge through innovation and strategic adaptation.
Zoetis (ZTS) Receives New Analyst Rating from Keybanc | ZTS Stock News
Zoetis (ZTS) Receives New Analyst Rating from Keybanc | ZTS Stock News
Zoetis (ZTS) Coverage Initiated with Sector Weight Rating by KeyBanc
Zoetis (ZTS) Coverage Initiated with Sector Weight Rating by KeyBanc
A Look Into Zoetis Inc's Price Over Earnings
In the current market session, Zoetis Inc. (NYSE: ZTS) price is at $117.53, after a 0.38% spike. However, over the past month, the stock fell by 20.42% , and in the past year, by 34.17% . Shareholder...
Zoetis to Participate in the Piper Sandler 37th Annual Healthcare Conference
Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:30 a.m. ET. Kristin Peck, Chief Executive Officer and Wetteny Joseph, ...
Zoetis to Participate in the Piper Sandler 37th Annual Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:30 a.m. ET. ...
Zoetis to Host Innovation Webcast
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host an Innovation Webcast at 8:30 a.m. ET on Tuesday, December 2, 2025, featuring Kristin Peck, Chief Executive O...
Zoetis (ZTS): Analyst Stifel Maintains Hold, Lowers Price Target to $130 | ZTS Stock News
Zoetis (ZTS): Analyst Stifel Maintains Hold, Lowers Price Target to $130 | ZTS Stock News
These stocks have been hit hard in 2025 but could surge by as much as 57% from here
Downtrodden names expected to come roaring back include Adobe, Block and Salesforce.
2 Outstanding Dividend Stocks That Are Too Cheap to Ignore
Both stocks trade at once-in-a-decade low valuations and have all-time high dividend yields. Each company leads in its niche, but both are battling through minor challenges.